In vitro activity of an evernimicin derivative, SCH27899, against anaerobic bacteria and Propionibacterium acnes.
The in vitro activity of SCH27899, a novel oligosaccharide antimicrobial agent, was compared with those of representatives of six classes of antimicrobial agents (piperacillin, clarithromycin, clindamycin, vancomycin, sitafloxacin and metronidazole) against clinical isolates of anaerobic bacteria and Propionibacterium acnes. Against Peptostreptococcus: spp. and Clostridium difficile, SCH27899 was the most potent (MIC(90) < 0.125 mg/L) of the agents examined. Besides these Gram-positive anaerobes, SCH27899 showed a moderate level of activity against Prevotella bivia, Prevotella intermedia and Porphyromonas: spp. (MIC(90)< or = 4 mg/L).
Tanaka
K
K
Institute of Anaerobic Bacteriology, Gifu University School of Medicine, 40 Tsukasa-machi Gifu, 500-8705, Japan.
Kato
N
N
Watanabe
K
K
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D011425:Propionibacterium acnes / Q000187:drug effects*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; C001202:evernimicin